Biomarkers in pediatrics: Children as biomarker orphans

Proteomics - Clinical Applications

Volumn 4, Issue 12, 2010, Pages 915-921

  Savage, William J ^a   Everett, Allen D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Pediatrics

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; AGE; DIAGNOSTIC VALUE; DISEASE SEVERITY; FALSE POSITIVE RESULT; GENETIC DISORDER; MASS SPECTROMETRY; MEDICAL RESEARCH; PEDIATRICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; RISK ASSESSMENT; SCREENING; SICKLE CELL ANEMIA; STANDARDIZATION; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CHILD; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PROGNOSIS; REFERENCE VALUES;

EID: 78649691629     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000062     Document Type: Review

References (42)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
2. Morrow, D. A., de Lemos, J. A., Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115, 949-952.
3. IOM, (Institute of Medicine). Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease, The National Academic Press, Washington, DC, 2010.
4. Woods, W. G., Gao, R. N., Shuster, J. J., Robison, L. L. et al., Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 2002, 346, 1041-1046.
5. Tsubono, Y., Hisamichi, S., A halt to neuroblastoma screening in Japan. N. Engl. J. Med. 2004, 350, 2010-2011.
6. Garg, U., Dasouki, M., Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: clinical and laboratory aspects. Clin. Biochem. 2006, 39, 315-332.
7. Honda, M., Tsuruta, R., Kaneko, T., Kasaoka, S. et al., Serum glial fibrillary acidic protein is a highly specific biomarker for traumatic brain injury in humans compared with S-100B and neuron-specific enolase. J. Trauma 2010, 69, 104-109.
8. Berger, R. P., Adelson, P. D., Pierce, M. C., Dulani, T. et al., Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J. Neurosurg. 2005, 103, 61-68.
9. Blennow, M., Hagberg, H., Rosengren, L., Glial fibrillary acidic protein in the cerebrospinal fluid: a possible indicator of prognosis in full-term asphyxiated newborn infants? Pediatr. Res. 1995, 37, 260-264.
10. Liu, L., Zheng, C. X., Peng, S. F., Zhou, H. Y. et al., Evaluation of urinary S100B protein level and lactate/creatinine ratio for early diagnosis and prognostic prediction of neonatal hypoxic-ischemic encephalopathy. Neonatology 2010, 97, 41-44.
11. Brousseau, D. C., Panepinto, J. A., Nimmer, M., Hoffmann, R. G., The number of people with sickle-cell disease in the United States: national and state estimates. Am. J. Hematol. 2010, 85, 77-78.
12. Panepinto, J. A., Magid, D., Rewers, M. J., Lane, P. A., Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J. Pediatr. 2000, 136, 201-208.
13. Grosse, S. D., Olney, R. S., Baily, M. A., The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl. Health Econ. Health Policy 2005, 4, 239-247.
14. Barker, D. J., Osmond, C., Forsen, T. J., Kajantie, E., et al., Trajectories of growth among children who have coronary events as adults. N. Engl. J. Med. 2005, 353, 1802-1809.
15. Osmond, C., Kajantie, E., Forsen, T. J., Eriksson, J. G., et al., Infant growth and stroke in adult life: the Helsinki birth cohort study. Stroke 2007, 38, 264-270.
16. Schoen, E. J., Baker, J. C., Colby, C. J., To, T. T., Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 2002, 110, 781-786.
17. Botkin, J. R., Clayton, E. W., Fost, N. C., Burke, W. et al., Newborn screening technology: proceed with caution. Pediatrics 2006, 117, 1793-1799.
18. Prosser, L. A., Kong, C. Y., Rusinak, D., Waisbren, S. L., Projected costs, risks, and benefits of expanded newborn screening for MCADD. Pediatrics 2010, 125, e286-e294.
19. Venditti, L. N., Venditti, C. P., Berry, G. T., Kaplan, P. B. et al., Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 2003, 112, 1005-1015.
20. Spiekerkoetter, U., Haussmann, U., Mueller, M., Ter Veld, F. et al., tandem mass spectrometry screening for very long-chain Acyl-Coa dehydrogenase deficiency: the value of second-tier enzyme testing. J. Pediatr. 2010, 157, 668-673.
21. Suzuki, M., Wiers, K., Brooks, E. B., Greis, K. D. et al., Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr. Res. 2009, 65, 530-536.
22. Urbina, E. M., Williams, R. V., Alpert, B. S., Collins, R. T. et al., Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009, 54, 919-950.
23. Horisberger, T., Harbarth, S., Nadal, D., Baenziger, O., et al., G-CSF and IL-8 for early diagnosis of sepsis in neonates and critically ill children - safety and cost effectiveness of a new laboratory prediction model: study protocol of a randomized controlled trial [ISRCTN91123847]. Crit. Care 2004, 8, R443-R450.
24. Printz, C., Collaboration is key to treating uncommon cancers: scientists and patients champion research in these rare diseases. Cancer 2010, 116, 2847-2849.
25. Tau, G. Z., Peterson, B. S., Normal development of brain circuits. Neuropsychopharmacology 2010, 35, 147-168.
26. Seibel, N. L., Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology Am. Soc. Hematol. Educ. Program 2008, 374-380.
27. Jung, B., Adeli, K., Clinical laboratory reference intervals in pediatrics: the CALIPER initiative. Clin. Biochem. 2009, 42, 1589-1595.
28. Wendler, D., Belsky, L., Thompson, K. M., Emanuel, E. J., Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. JAMA 2005, 294, 826-832.
29. Omenn, G. S., States, D. J., Adamski, M., Blackwell, T. W. et al., Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5, 3226-3245.
30. Singh, I., Rose, N., Biomarkers in psychiatry. Nature 2009, 460, 202-207.
31. Wertz, D. C., Fanos, J. H., Reilly, P. R., Genetic testing for children and adolescents. Who decides? JAMA 1994, 272, 875-881.
32. Daniels, S. R., Greer, F. R., Lipid screening and cardiovascular health in childhood. Pediatrics 2008, 122, 198-208.
33. Steiner, M. J., Brown, W. D., Liles, E., An assessment of the new lipid screening guidelines. Pediatrics 2008, 122, 904-905; author reply 906-907.
34. Olson, S., Robinson, S., Giffin, R., (Institute of Medicine). Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary, The National Academic Press, New York 2009.
35. Kiringoda, R., Thurm, A. E., Hirschtritt, M. E., Koziol, D. et al., Risks of propofol sedation/anesthesia for imaging studies in pediatric research: eight years of experience in a clinical research center. Arch. Pediatr. Adolesc. Med. 2010, 164, 554-560.
36. IOM, (Institute Of Medicine). Cancer Biomarkers. The Promises and Challenges of Improving Detection and Treatment, National Academic Press, Washington, DC, 2007.
37. Haase, M., Bellomo, R., Devarajan, P., Schlattmann, P., Haase-Fielitz, A., Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 2009, 54, 1012-1024.
38. Mannucci, P. M., Tuddenham, E. G., The hemophilias - from royal genes to gene therapy. N. Engl. J. Med. 2001, 344, 1773-1779.
39. Remuzzi, G., Galbusera, M., Noris, M., Canciani, M. T. et al., von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002, 100, 778-785.
40. Kimpimaki, T., Kulmala, P., Savola, K., Vahasalo, P. et al., Disease-associated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk. Childhood Diabetes in Finland Study Group. J. Clin. Endocrinol. Metab. 2000, 85, 1126-1132.
41. Matt, P., Schoenhoff, F., Habashi, J., Holm, T. et al., Circulating transforming growth factor-beta in Marfan syndrome. Circulation 2009, 120, 526-532.
42. van Casteren, N. J., van der Linden, G. H., Hakvoort-Cammel, F. G., Hahlen, K. et al., Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr. Blood Cancer 2009, 52, 108-112.